Keywords: biomarin, sees, 2nd-qtr, loss, rocket, ascent, acquisition
BioMarin sees 2nd-qtr loss rocket on Ascent acquisition
Article | 16 August 2004
California, USA-headquartered BioMarin saw its second-quarter net lossrocket to $55.6 million, or $0.86 a share, compared to $9.1 million, or $0.14 per share, for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
